The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
September 30, 2024
View Complete Issue         Table of Contents 2019 
Iptacopan (Fabhalta) for Paroxysmal Nocturnal Hemoglobinuria (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Iptacopan (Fabhalta) for Paroxysmal Nocturnal Hemoglobinuria (online only)
September 30, 2024 (Issue: 1712)
The FDA has approved the complement factor B inhibitor iptacopan (Fabhalta – Novartis) for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults. Iptacopan is the first oral drug to be approved in the US for this indication....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Iptacopan (Fabhalta) for Paroxysmal Nocturnal Hemoglobinuria (online only)
Article code: 1712e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.